Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VCEL
CUSIPN/A
Phone800-556-0311
Debt
Debt-to-Equity Ratio0.75
Current Ratio3.48
Quick Ratio3.19
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$63.92 million
Price / Sales6.31
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book16.92
Profitability
EPS (Most Recent Fiscal Year)($0.50)
Net Income$-17,280,000.00
Net Margins-20.89%
Return on Equity-67.15%
Return on Assets-27.10%
Miscellaneous
Employees205
Outstanding Shares36,680,000
Vericel (NASDAQ:VCEL) Frequently Asked Questions
What is Vericel's stock symbol?
Vericel trades on the NASDAQ under the ticker symbol "VCEL."
How were Vericel's earnings last quarter?
Vericel Corp (NASDAQ:VCEL) issued its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.08. The biotechnology company had revenue of $18.03 million for the quarter, compared to the consensus estimate of $16.51 million. Vericel had a negative return on equity of 67.15% and a negative net margin of 20.89%. View Vericel's Earnings History.
When is Vericel's next earnings date?
What price target have analysts set for VCEL?
5 brokers have issued 1 year target prices for Vericel's shares. Their forecasts range from $14.00 to $17.00. On average, they anticipate Vericel's share price to reach $15.25 in the next year. View Analyst Ratings for Vericel.
Who are some of Vericel's key competitors?
Some companies that are related to Vericel include Denali Therapeutics (DNLI), Audentes Therapeutics (BOLD), Solid Biosciences (SLDB), Acorda Therapeutics (ACOR), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), Iovance Biotherapeutics (IOVA), DBV Technologies (DBVT), BAVARIAN NORDIC/S (BVNRY), Coherus Biosciences (CHRS), La Jolla Pharmaceutical (LJPC), Heska (HSKA), Fate Therapeutics (FATE), Voyager Therapeutics (VYGR) and Novavax (NVAX).
Who are Vericel's key executives?
Vericel's management team includes the folowing people:
- Mr. Dominick C. Colangelo, CEO, Pres & Director (Age 54)
- Mr. Gerard J. Michel, CFO & VP of Corp. Devel. (Age 55)
- Mr. Daniel R. Orlando, Chief Operating Officer (Age 53)
- Ms. Jacquelyn Fahey Sandell, VP, Gen. Counsel & Corp. Sec.
- Ms. Heidi Hassen, Sr. Director of HR
Has Vericel been receiving favorable news coverage?
Media stories about VCEL stock have trended somewhat positive on Saturday, according to Accern. Accern identifies negative and positive media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vericel earned a news impact score of 0.09 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 45.77 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Vericel's major shareholders?
Vericel's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Archon Capital Management LLC (6.52%), PNC Financial Services Group Inc. (1.73%), Millennium Management LLC (1.69%), First Washington CORP (1.52%), Next Century Growth Investors LLC (1.01%) and Russell Investments Group Ltd. (0.87%). Company insiders that own Vericel stock include Alan L Rubino, Daniel Orlando, Dominick Colangelo and Paul K Wotton. View Institutional Ownership Trends for Vericel.
Which institutional investors are selling Vericel stock?
VCEL stock was sold by a variety of institutional investors in the last quarter, including Archon Capital Management LLC, First Washington CORP, Alpine Global Management LLC and Dorsey & Whitney Trust CO LLC. Company insiders that have sold Vericel company stock in the last year include Daniel Orlando, Dominick Colangelo and Paul K Wotton. View Insider Buying and Selling for Vericel.
Which institutional investors are buying Vericel stock?
VCEL stock was bought by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc., Millennium Management LLC, Next Century Growth Investors LLC, Russell Investments Group Ltd., Timpani Capital Management LLC, EAM Global Investors LLC, JPMorgan Chase & Co. and Tibra Equities Europe Ltd. View Insider Buying and Selling for Vericel.
How do I buy shares of Vericel?
Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vericel's stock price today?
One share of VCEL stock can currently be purchased for approximately $11.00.
How big of a company is Vericel?
Vericel has a market capitalization of $401.66 million and generates $63.92 million in revenue each year. The biotechnology company earns $-17,280,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Vericel employs 205 workers across the globe.
How can I contact Vericel?
Vericel's mailing address is 64 SIDNEY ST., CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]
MarketBeat Community Rating for Vericel (VCEL)
MarketBeat's community ratings are surveys of what our community members think about Vericel and other stocks. Vote "Outperform" if you believe VCEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
